CBPO (US16938C1062)
China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based pharmaceutical products in China. The Company is approved to sell human albumin. The Company sells its products to customers in the People’s Republic of China, mainly hospitals and inoculation centers directly or through approved distributors.
Average yearly return: 66%
Yield: N/A
Top performer
August 4, 2016:
China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based pharmaceutical products in China. The Company is approved to sell human albumin. The Company sells its products to customers in the People’s Republic of China, mainly hospitals and inoculation centers directly or through approved distributors.
Market: Nasdaq
Fair value: $131
Discount: 5%
Fair value: $131
Average yearly return: 66%
Yield: N/A
Top performer
August 4, 2016:
China Biologic Reports Financial Results 16Q2
Total Sales Up 23.4% with Non-GAAP Net Income Up 31.3% YoY in RMB terms, or Up 15.5% YoY to $91.4 Million and 23.1% YoY to $35.2 Million in USD terms, respectively--1H16 Total Sales Up 26.2% with Non-GAAP Net Income Up 30.6% YoY in RMB terms, or Up 18.5% YoY to $177.0 Million and 22.6% YoY to $65.6 Million in USD terms, respectively
No comments:
Post a Comment